欣瑞来 在华获批

Core Viewpoint - Merck has received approval from the National Medical Products Administration (NMPA) in China for its breakthrough therapy, ASI (injectable sotatercept), aimed at treating adult patients with pulmonary arterial hypertension (PAH) classified as WHO functional class (FC) II-III, to improve their exercise capacity and WHO functional class [1] Group 1 - ASI is a novel biological agent targeting the underlying causes of PAH [1] - The approval is based on data from the Phase III clinical trial STELLAR [1]